The mission of the Bioinformatics Shared Resource (BISR) is to provide bioinformatic and biostatistical collaboration, consultation, and quantitative research resources to clinical, laboratory, and prevention scientists engaged in the planning, conduct, analysis, and interpretation of research studies that use modern high-throughput technologies from molecular biology. Additionally, members of the BISR collaborate with oncology research scientists to develop bioinformatic and biostatistical methods to improve the efficiency of current and future basic science, therapeutic, diagnostic, prevention, and intervention studies. Members of the BISR have experience with mRNA expression microarrays from Affymetrix, Agilent, and Illumina, proteomics using mass spectrometry or two-dimensional polyacrylamide gel electrophoresis;serial analysis of gene expression;tissue microarrays;array comparative genomic hybridization;single nucleotide polymorphism chips;methylation arrays;microRNA arrays;exon tiling arrays;real-time polymerase chain reaction;and reverse-phase protein lysate arrays. The BISR provides advice on choosing technology platforms, experimental design, sample size and power computations, data preprocessing, statistical analysis, and bioinformatic interpretation. The services of the resource are directed toward three goals: (1) to ensure that all high-throughput experiments at M.D. Anderson are properly analyzed and interpreted, (2) to play a direct role in the planning and design of experiments that use these technologies, and (3) to provide educational programs in bioinformatics methods. During the previous funding period, the BISR assisted 244 investigators from 20 different programs. Use of the BISR doubled during the previous five years, and the number of publications by users of the BISR grew from 33 during the first year to 65 during the most recent year. In the future, we remain committed to providing support for the design and analysis of experiments using cutting-edge technologies and will work with M.D. Anderson researchers to understand the nature of the data generated from novel technologies. Where possible, we are standardizing our analyses and report generation by developing templates in Sweave, a tool that enhances the reproducibility of statistical analyses. We also plan to enhance our ability to offer sequence-based bioinformatics services such as ChlP-on-chip and motif finding. Finally, we are exploring innovative ways to integrate data, algorithms, and reports.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA016672-36
Application #
8310862
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
36
Fiscal Year
2011
Total Cost
$166,099
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Chang, Geraldine H; Kurzrock, Razelle; Tran, Lisa et al. (2018) TP53 mutations and number of alterations correlate with maximum standardized uptake value (SUVmax) determined by positron emission tomography/computed tomography (PET/CT) [18F] fluorodeoxyglucose (18F-FDG PET). Oncotarget 9:14306-14310
Abaza, Yasmin; Cortes, Jorge; Ravandi, Farhad et al. (2018) Prognostic significance of hyperdiploidy in adult acute myeloid leukemia. Am J Hematol 93:E357-E360
Ellrott, Kyle; Bailey, Matthew H; Saksena, Gordon et al. (2018) Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines. Cell Syst 6:271-281.e7
White, Matthew C; Schroeder, Rebecca D; Zhu, Keyi et al. (2018) HRI-mediated translational repression reduces proteotoxicity and sensitivity to bortezomib in human pancreatic cancer cells. Oncogene 37:4413-4427
Abaza, Yasmin; Hidalgo-Lopez, Juliana E; Verstovsek, Srdan et al. (2018) Phase I study of ruxolitinib in previously treated patients with low or intermediate-1 risk myelodysplastic syndrome with evidence of NF-kB activation. Leuk Res 73:78-85
McGrail, Daniel J; Federico, Lorenzo; Li, Yongsheng et al. (2018) Multi-omics analysis reveals neoantigen-independent immune cell infiltration in copy-number driven cancers. Nat Commun 9:1317
Li, Carrie J; Jiang, Changying; Liu, Yang et al. (2018) Pleiotropic Action of Novel Bruton's Tyrosine Kinase Inhibitor BGB-3111 in Mantle Cell Lymphoma. Mol Cancer Ther :
Morita, Kiyomi; Kantarjian, Hagop M; Wang, Feng et al. (2018) Clearance of Somatic Mutations at Remission and the Risk of Relapse in Acute Myeloid Leukemia. J Clin Oncol 36:1788-1797
Raber, Benjamin; Bea, Vivian J; Bedrosian, Isabelle (2018) How Does MR Imaging Help Care for My Breast Cancer Patient? Perspective of a Surgical Oncologist. Magn Reson Imaging Clin N Am 26:281-288
Li, Roger; Metcalfe, Michael J; Ferguson 3rd, James E et al. (2018) Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121:244-251

Showing the most recent 10 out of 12418 publications